More Than 125 Customers Worldwide Live on Vault CRM as Veeva Accelerates the Industry's Agentic Transformation
MWN-AI** Summary
Veeva Systems has announced a significant milestone, with over 125 customers now live on its Vault CRM platform, reflecting its growing leadership in agentic customer relationship management (CRM) for the life sciences industry. This includes a diverse range of clients, from some of the top 20 biopharmaceutical companies to various enterprises across markets in the U.S., Europe, and Japan. The introduction of Veeva AI alongside Vault CRM has been pivotal in propelling the industry's shift toward more personalized and effective customer engagement strategies.
Vault CRM delivers a robust platform designed to support the entire product lifecycle and facilitate complex customer interactions, from initial market preparations and product launches to enhancing the performance of established brands. According to Arno Sosna, president of the CRM Suite at Veeva, this momentum showcases the platform's extensive functionality, compliance capabilities, and tailored workflows that cater to commercial and medical teams.
Veeva's evolving approach not only highlights its commitment to customer success but also leads to product excellence within the industry. The company's proactive measures include updating the end-of-support date for its legacy CRM solution from September 2030 to December 2029, underscoring its focus on transitioning customers to the more advanced Vault CRM system.
Part of the Vault CRM Suite, which also encompasses applications such as Events Management and Patient CRM, Vault CRM is positioned as the technological backbone for biopharmaceutical companies of all sizes, reinforcing Veeva's dedication to innovation and stakeholder balance. With over 1,500 clients, Veeva continues to redefine the landscape of life sciences CRM through its cloud-based offerings and forward-thinking strategies.
MWN-AI** Analysis
Veeva Systems (NYSE: VEEV) has marked a significant milestone with over 125 customers now live on its Vault CRM platform, solidifying its leadership position in the agentic CRM space for the life sciences sector. As companies globally embrace this advanced CRM solution, investors should take note of the implications for Veeva's growth trajectory and market positioning.
The adoption of Vault CRM by major biopharmaceutical players highlights its effectiveness in enhancing customer engagement and operational efficiency. This transition to an agentic customer relationship management model allows firms to leverage AI-powered insights, which can enhance decision-making throughout the product lifecycle. With comprehensive features designed for compliance and deep industry functionality, Veeva is well-positioned to cater to the complex needs of the life sciences sector.
As Vault CRM gains traction, its contributions to Veeva's revenue streams become increasingly relevant. The anticipated growth in customer numbers and the upcoming upgrade path for Veeva CRM, effective until December 2029, may provide a further boost to client retention and sales conversions. Given the shift towards integrating technology across the life sciences, Veeva's commitment to innovation strengthens its competitive edge, which may appeal to long-term investors.
Potential investors should closely monitor Veeva's quarterly performance and user adoption rates for Vault CRM, as continual engagement can direct the company's revenue growth and product enhancements. Moreover, analysts should keep an eye on risks outlined in Veeva's SEC filings that could impact future profitability, as the tech landscape for life sciences evolves.
In conclusion, Veeva Systems represents a strong opportunity for stakeholders, symbolized by its successful transition to a more agentic CRM approach, leveraging AI and extensive functionalities to meet the unique demands of the life sciences market. Investors should be attentive to developments that may shape the company's trajectory in this burgeoning sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
With broad industry success and the availability of Veeva AI, Vault CRM is the leader in agentic CRM for life sciences
PLEASANTON, Calif., March 3, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 125 customers — from multiple top 20 biopharmas to companies across all major regions including the U.S., Europe and Japan — are now live on Veeva Vault CRM, the next generation of CRM for life sciences. With the success of Vault CRM and the availability of Veeva AI, Veeva is accelerating the industry's move to agentic CRM.
The strong momentum behind Vault CRM reflects the clear business value of its deep industry and regional functionality, compliance, workflows, and agents. Vault CRM provides the foundation commercial and medical teams require to support the full product lifecycle and complex customer engagements, from initial market preparation and launches to optimizing the performance of mature brands.
"More than 125 customers are already live with Vault CRM and on the fast path to agentic customer engagement," said Arno Sosna, president, CRM Suite, Veeva. "We're expanding that impact across the industry as we lead with a focus on customer success and product excellence."
With the success of Vault CRM and a well-established upgrade path, Veeva has updated the end-of-support date for Veeva CRM from September 2030 to the end of December 2029.
Vault CRM is part of the Vault CRM Suite of applications that provide the technology foundation for commercial execution for biopharma companies of all sizes in all regions. Vault CRM Suite also includes Events Management, Service Center, Campaign Manager, and Patient CRM.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov.
Contact: | |
Maria Scurry |
SOURCE Veeva Systems
FAQ**
How does Veeva Systems Inc. Class A VEEV plan to maintain its leadership in the agentic CRM space amidst increasing competition in the life sciences industry?
What specific benefits have been observed by the 1customers now using Vault CRM from Veeva Systems Inc. Class A VEEV in terms of customer engagement and operational efficiency?
What strategies will Veeva Systems Inc. Class A VEEV implement to support existing customers as they transition from Veeva CRM to Vault CRM before the end-of-support deadline in December 2029?
How is Veeva Systems Inc. Class A VEEV utilizing Veeva AI to enhance the functionality of Vault CRM and improve customer experiences in the life sciences sector?
**MWN-AI FAQ is based on asking OpenAI questions about Veeva Systems Inc. Class A (NYSE: VEEV).
NASDAQ: VEEV
VEEV Trading
-2.0% G/L:
$190.50 Last:
316,099 Volume:
$194.27 Open:
